Carnitor SF Side Effects

Please note - some side effects for Carnitor SF may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA.

Side Effects of Carnitor SF - for the Consumer

Carnitor SF Solution

All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome when using Carnitor SF Solution:

Bad taste in mouth; diarrhea; mild muscle weakness; nausea; stomach cramps; unpleasant body odor; vomiting.

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); seizures.

This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.

Side Effects by Body System - for Healthcare Professionals

Gastrointestinal

Gastrointestinal side effects associated with levocarnitine oral solution may be minimized or avoided by slow consumption or greater dilution of the solution. Decreasing the dosage may also help alleviate gastrointestinal effects.

Gastrointestinal side effects are generally mild and have been reported in 41% of patients.

Taste fatigue may be reduced by mixing the oral solution with drinks or liquid foods.

Gastrointestinal side effects have included transient nausea and vomiting, nausea, gastritis, and taste fatigue. Gastrointestinal side effects, in chronic hemodialysis patients, for levocarnitine in relation to placebo therapy have included transient nausea (5% to 12% vs 10%), vomiting (9% to 21% vs 16%), and diarrhea (9% to 35% vs 19%) abdominal pain (5% to 21% vs 17%), anorexia (3% to 6% vs 3%), constipation (3% vs 6%), dyspepsia (5% to 9% vs 10%), gastrointestinal disorder (2% to 6% vs 2%), melena (2% to 6% vs 3%), and taste perversion (2% to 9% vs 0%).

Nervous system

Nervous system side effects have included seizures in patients with or without preexisting seizure activity, and increases in seizure frequency and/or severity in patients with preexisting seizure activity.

Nervous system side effects, in chronic hemodialysis patients, for levocarnitine in relation to placebo therapy have included anxiety (1% to 2% vs 5%), dizziness (10% to 18% vs 11%), hypertonia (1% to 3% vs 5%), insomnia (3% to 6% vs 6%), paresthesia (3% to 12% vs 3%), and vertigo (2% to 6% vs 0%).

Metabolic

There are reports from clinical trials of significant hypertriglyceridemia associated with high doses of levocarnitine (3 g/day) given to uremic dialysis patients.

Metabolic side effects have included hypertriglyceridemia, decreases in triglyceride levels, and no effects on triglyceride levels. Metabolic side effects, in hemodialysis patients, for levocarnitine in relation to placebo therapy have included hypercalcemia (6% to 15% vs 3%), hyperkalemia (6% vs 6%), and hypervolemia (3% to 12% vs 17%).

Other

Other side effects have included body odor (11%). Other side effects, in chronic hemodialysis patients, for levocarnitine in relation to placebo therapy have included accidental injury (8% to 12% vs 10%), fever (5% to 12% vs 5%), peripheral edema (3% to 5% vs 3%), weight decrease (3% to 8% vs 3%), and weight increase (2% to 6% vs 2%), headache (3% to 36% vs 16%), back pain (6% to 9% vs 10%), and pain (21% to 35% vs 49%).

Body odor may be decreased or minimized by decreasing the dosage.

Local

Local side effects, in chronic hemodialysis patients, for levocarnitine in relation to placebo have included injection site reactions (27% to 38% vs 59%).

Musculoskeletal

Musculoskeletal side effects, in chronic hemodialysis patients, for levocarnitine in relation to placebo therapy have included asthenia (8% to 12% vs 8%) and leg cramps (4% to 8% vs 13%). Mild myasthenia has occurred in uremic patients receiving D,L-carnitine (but not levocarnitine).

Hematologic

Hematologic side effects, in chronic hemodialysis patients, for levocarnitine in relation to placebo therapy have included anemia (3% to 12% vs 3%). Other side effects have included significant increases in platelet aggregation and lack of effect on platelet activity.

There have been reports from clinical trials of significant increases in platelet aggregation associated with high doses of levocarnitine (3 g/day) given to hemodialysis patients.

Endocrine

Endocrine side effects, in chronic hemodialysis patients, for levocarnitine in relation to placebo therapy have included parathyroid disorder (2% to 6% vs 2%).

Respiratory

Respiratory side effects, in chronic hemodialysis patients, for levocarnitine in relation to placebo therapy have included bronchitis (3% to 5% vs 0%), cough increase (9% to 18% vs 16%), dyspnea (3% to 11% vs 19%), pharyngitis (15% to 27% vs 33%), rhinitis (6% to 11% vs 10%), and sinusitis (2% to 3% vs 5%).

Dermatologic

Dermatologic side effects, in chronic hemodialysis patients, for levocarnitine in relation to placebo therapy have included pruritus (3% to 8% vs 13%) and rash (3% to 5% vs 3%).

Ocular

Ocular side effects, in chronic hemodialysis patients, for levocarnitine in relation to placebo therapy have included amblyopia (3% to 6% vs 2%) and eye disorder (3% to 6% vs 3%).

Genitourinary

Genitourinary side effects, in chronic hemodialysis patients, for levocarnitine in relation to placebo therapy have included urinary tract infection (2% to 3% vs 6%) and kidney failure (6% vs 5%).

Cardiovascular

Cardiovascular side effects, in chronic hemodialysis patients, for levocarnitine in relation to placebo therapy have included arrhythmia (2% to 3% vs 5%), atrial fibrillation (2% to 6% vs 0%), cardiovascular disorder (3% to 6% vs 6%), chest pain (6% to 15% vs 14%), electrocardiogram abnormalities (2% to 6% vs 0%), hemorrhage (2% to 9% vs 6%), hypertension (18% to 21% vs 14%), hypotension (3% to 19% vs 19%), palpitations (3% to 8% vs 0%), tachycardia (5% to 9% vs 5%), and vascular disorder (2% to 6% vs 2%).

Hypersensitivity

Hypersensitivity side effects, in chronic hemodialysis patients, for levocarnitine in relation to placebo therapy have included allergic reactions (2% to 6% vs 5%).

General

Causality has not been determined for side effects mentioned in chronic hemodialysis patients.

Psychiatric

Psychiatric side effects, in chronic hemodialysis patients, for levocarnitine in relation to placebo therapy have included depression (5% to 6% vs 3%) and drug dependence (2% to 6% vs 2%).

Immunologic

Immunologic side effects, in chronic hemodialysis patients, for levocarnitine in relation to placebo therapy have included flu syndrome (15% to 29% vs 40%), infection (10% to 24% vs 17%).

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of information provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.